[HTML][HTML] Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study
C Cursiefen, E Viaud, F Bock, B Geudelin, A Ferry… - Ophthalmology, 2014 - Elsevier
Objective Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor
substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding …
substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding …
[HTML][HTML] Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration
…, S Al-Mahmood, S Colin, A Ferry… - … & Visual Science, 2012 - iovs.arvojournals.org
Purpose.: Aganirsen, an antisense oligonucleotide inhibiting insulin receptor substrate (IRS)-1
expression, has been shown to promote the regression of pathologic corneal …
expression, has been shown to promote the regression of pathologic corneal …
Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin‐converting enzyme inhibition in serum
…, C Funck‐Brentano, V Lecocq, A Ferry… - Clinical …, 1990 - Wiley Online Library
Food has been shown to reduce the bioavailability of the angiotensin‐converting enzyme
inhibitor captopril, but not the bioavailability of inhibitors administered as ester prodrugs. …
inhibitor captopril, but not the bioavailability of inhibitors administered as ester prodrugs. …
The Antiangiogenic Insulin Receptor Substrate-1 Antisense Oligonucleotide Aganirsen Impairs AU-Rich mRNA Stability by Reducing 14-3-3β–Tristetraprolin Protein …
S Colin, B Darné, A Kadi, A Ferry, M Favier… - … of Pharmacology and …, 2014 - ASPET
Increased inflammation and aberrant angiogenesis underlie psoriasis. Here, we report that
the inhibition of insulin receptor substrate-1 (IRS-1) expression with aganirsen resulted in a …
the inhibition of insulin receptor substrate-1 (IRS-1) expression with aganirsen resulted in a …
Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patient
D Deplanque, C Fetro, A Ferry, P Lechat, T Beghyn… - Therapies, 2023 - Elsevier
The repurposing of a medicine already on the market to a new indication could be an
opportunity to respond rapidly to a therapeutic need not yet covered, particularly in the context of …
opportunity to respond rapidly to a therapeutic need not yet covered, particularly in the context of …
[PDF][PDF] Quels sont les leviers financiers existants?
A Ferry - La Presse Médicale, 2010 - academia.edu
Les médicaments orphelins aujourd’hui constituent une réalité bien tangible puisque l’on
compte 657 désignations et 56 AMM. De plus en plus validé, ce modèle économique est une …
compte 657 désignations et 56 AMM. De plus en plus validé, ce modèle économique est une …
Laboratoire CTRS, le défi des maladies orphelines
C Cailliot, C Pompon, A Ferry - Innovations & Thérapeutiques en Oncologie, 2020 - jle.com
Laboratoires CTRS, specialized in public-private partnerships for rare diseases, aims to provide
patients with highly effective drugs against rare and ultra-rare diseases. Our priority is to …
patients with highly effective drugs against rare and ultra-rare diseases. Our priority is to …
La Sécurité Sociale depuis les ordonnances de 1967
A Ferry - Revue d'économie politique, 1972 - JSTOR
La protection sociale, un droit pour les travailleurs.—La prépa ration des Ordonnances de
1967.—Les Ordonnances du 21 août 1967.—Vers l'instauration d'un régime d'assurance …
1967.—Les Ordonnances du 21 août 1967.—Vers l'instauration d'un régime d'assurance …
[CITATION][C] Presenting a research project on rare diseases to industrial companies
A Ferry - Presse Medicale (Paris, France: 1983), 2012 - europepmc.org
… Ferry A 1 …
[CITATION][C] Conference 1. An economic observatory for orphan drugs: myth or reality?
C Duguet, A Ferry - Medecine Sciences: M/S, 2014 - europepmc.org
… Ferry A 2 …